Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATC CNSX:ETI NYSEARCA:FPE NASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATCAtotech$22.71$21.22$18.06▼$25.94$4.42B0.631.09 million shsN/AETIEnviroleach Technologies$0.00$0.00▼$0.00N/AN/AN/A17,860 shsFPEFirst Trust Preferred Securities and Income ETF$18.38+0.2%$18.02$16.77▼$18.39$6.18B0.471.46 million shs1.70 million shsHALOHalozyme Therapeutics$75.85-0.6%$65.95$42.01▼$77.60$8.93B1.191.87 million shs1.15 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATCAtotech0.00%0.00%0.00%0.00%0.00%ETIEnviroleach Technologies0.00%0.00%0.00%0.00%0.00%FPEFirst Trust Preferred Securities and Income ETF+0.16%+0.93%+1.55%+3.72%+1.77%HALOHalozyme Therapeutics-0.63%-0.29%+12.75%+42.71%+20.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATCAtotech$22.71$21.22$18.06▼$25.94$4.42B0.631.09 million shsN/AETIEnviroleach Technologies$0.00$0.00▼$0.00N/AN/AN/A17,860 shsFPEFirst Trust Preferred Securities and Income ETF$18.38+0.2%$18.02$16.77▼$18.39$6.18B0.471.46 million shs1.70 million shsHALOHalozyme Therapeutics$75.85-0.6%$65.95$42.01▼$77.60$8.93B1.191.87 million shs1.15 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATCAtotech0.00%0.00%0.00%0.00%0.00%ETIEnviroleach Technologies0.00%0.00%0.00%0.00%0.00%FPEFirst Trust Preferred Securities and Income ETF+0.16%+0.93%+1.55%+3.72%+1.77%HALOHalozyme Therapeutics-0.63%-0.29%+12.75%+42.71%+20.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATCAtotech 0.00N/AN/AN/AETIEnviroleach Technologies 0.00N/AN/AN/AFPEFirst Trust Preferred Securities and Income ETF 0.00N/AN/AN/AHALOHalozyme Therapeutics 2.33Hold$67.11-11.52% DownsideCurrent Analyst Ratings BreakdownLatest HALO, ETI, ANO, ATC, and FPE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025HALOHalozyme TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/18/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $80.008/7/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$60.00 ➝ $63.008/6/2025HALOHalozyme TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$78.00 ➝ $91.008/6/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $75.008/6/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$62.00 ➝ $75.007/16/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$58.00 ➝ $60.007/10/2025HALOHalozyme TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$55.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATCAtotech$1.50B2.95$1.15 per share19.72$4.24 per share5.36ETIEnviroleach TechnologiesN/AN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/AN/AN/AN/AN/AHALOHalozyme Therapeutics$1.02B8.74$4.62 per share16.41$2.86 per share26.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATCAtotech$7.50M$0.6137.23∞N/A8.14%20.32%5.25%N/AETIEnviroleach TechnologiesN/AN/A0.00N/AN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/A0.00∞N/AN/AN/AN/AN/AHALOHalozyme Therapeutics$444.09M$4.3717.3612.190.4247.28%150.85%29.19%10/30/2025 (Estimated)Latest HALO, ETI, ANO, ATC, and FPE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HALOHalozyme Therapeutics$1.23$1.54+$0.31$1.33$282.66 million$325.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATCAtotechN/AN/AN/AN/AN/AETIEnviroleach TechnologiesN/AN/AN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETF$1.035.60%N/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATCAtotech1.891.901.45ETIEnviroleach TechnologiesN/AN/AN/AFPEFirst Trust Preferred Securities and Income ETFN/AN/AN/AHALOHalozyme Therapeutics4.548.367.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATCAtotech94.57%ETIEnviroleach TechnologiesN/AFPEFirst Trust Preferred Securities and Income ETFN/AHALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipATCAtotech49.90%ETIEnviroleach TechnologiesN/AFPEFirst Trust Preferred Securities and Income ETFN/AHALOHalozyme Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATCAtotech4,033194.66 million97.53 millionNot OptionableETIEnviroleach Technologies147,000N/AN/ANot OptionableFPEFirst Trust Preferred Securities and Income ETFN/A336.30 millionN/ANot OptionableHALOHalozyme Therapeutics390116.97 million113.57 millionOptionableHALO, ETI, ANO, ATC, and FPE HeadlinesRecent News About These CompaniesStrs Ohio Makes New Investment in Halozyme Therapeutics, Inc. $HALO5 hours ago | marketbeat.comMRA Advisory Group Purchases New Shares in Halozyme Therapeutics, Inc. $HALOSeptember 16 at 6:28 AM | marketbeat.comSwedbank AB Has $16.42 Million Stock Position in Halozyme Therapeutics, Inc. $HALOSeptember 16 at 4:03 AM | marketbeat.comAshton Thomas Private Wealth LLC Purchases New Shares in Halozyme Therapeutics, Inc. $HALOSeptember 15 at 3:43 AM | marketbeat.comGoldman Sachs Group Inc. Sells 331,718 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 15 at 3:42 AM | marketbeat.comFocus Partners Wealth Purchases 44,260 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 15 at 3:18 AM | marketbeat.comHodges Capital Management Inc. Has $12.35 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALOSeptember 14 at 5:37 AM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) CFO Sells $1,514,200.00 in StockSeptember 13, 2025 | marketbeat.comIntech Investment Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. $HALOSeptember 13, 2025 | marketbeat.com8,083 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Fred Alger Management LLCSeptember 13, 2025 | marketbeat.comInsider Selling: Halozyme Therapeutics (NASDAQ:HALO) CFO Sells 20,000 Shares of StockSeptember 12, 2025 | insidertrades.comUnited Services Automobile Association Acquires New Shares in Halozyme Therapeutics, Inc. $HALOSeptember 12, 2025 | marketbeat.comGreat Lakes Advisors LLC Buys 98,190 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 11, 2025 | marketbeat.comDoes Halozyme Stock Offer More Potential After Its Recent Strong Price Run in 2025?September 11, 2025 | uk.finance.yahoo.comHalozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High - Should You Buy?September 10, 2025 | marketbeat.comRedwood Investments LLC Purchases 8,146 Shares of Halozyme Therapeutics, Inc. $HALOSeptember 10, 2025 | marketbeat.comTeza Capital Management LLC Acquires Shares of 8,976 Halozyme Therapeutics, Inc. $HALOSeptember 10, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires Shares of 182,354 Halozyme Therapeutics, Inc. $HALOSeptember 10, 2025 | marketbeat.comAxsome Therapeutics Stock Sees RS Rating Rise To 82September 9, 2025 | msn.com5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate CutsSeptember 9, 2025 | zacks.comDianthus Therapeutics Stock Earns RS Rating UpgradeSeptember 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCan Identity Security Fuel CrowdStrike’s Next Growth Phase?By Chris Markoch | August 22, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025MongoDB Roars Back to Life: It’s Not Too Late to Buy MoreBy Thomas Hughes | August 27, 2025CrowdStrike at a Crossroads: AI Halo vs. RisksBy Chris Markoch | August 28, 2025Who Won and Who Lost in Nuclear Energy’s Q2 EarningsBy Leo Miller | August 20, 2025HALO, ETI, ANO, ATC, and FPE Company DescriptionsAtotech NYSE:ATCAtotech Limited, a chemicals technology company, provides specialty electroplating and surface finishing solutions worldwide. The company operates through two segments, Electronics (EL) and General Metal Finishing (GMF). The EL segment manufactures and supplies chemistry, production equipment, software, and services to the electronics industry, which include printed circuit board manufacturers, package substrate makers, and semiconductor companies. Its products and technologies serve the principal electronics end-markets, including communication, computer, automotive, industrial, medical, aerospace, and military industries. The GMF segment provides chemistry, production technology, and services to the surface finishing industries in various areas of application. Its products and technologies serve the primary surface finishing end-markets comprising the automotive, consumer electronics, construction, sanitary, white goods, and oil and gas industries. The company also offers on-site support and training services. Atotech Limited was founded in 1851 and is headquartered in Berlin, Germany.Enviroleach Technologies CNSX:ETIEnviroMetal Technologies Inc. develops and markets technologies for the extraction of precious and other valuable metals from the mine products and electronic waste in the primary and secondary metal sectors. The company's technologies are used in the electronic waste processing industry to recover gold and other valuable metals from PCBA; and the mining industry for the recovery of gold from of ores and concentrates. It also operates E-waste and mineral processing facility. The company was formerly known as EnviroLeach Technologies Inc. and changed its name to EnviroMetal Technologies Inc. in August 2021. EnviroMetal Technologies Inc. was incorporated in 2016 and is headquartered in Burnaby, Canada.First Trust Preferred Securities and Income ETF NYSEARCA:FPE$18.38 +0.03 (+0.16%) Closing price 09/16/2025 04:10 PM EasternExtended Trading$18.38 0.00 (-0.03%) As of 09/16/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The First Trust Preferred Securities and Income ETF (FPE) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is an actively managed fund that attempts to generate income by investing globally in preferred equities and income producing debt across the market cap spectrum. FPE was launched on Feb 12, 2013 and is managed by First Trust.Halozyme Therapeutics NASDAQ:HALO$75.85 -0.48 (-0.63%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$74.61 -1.24 (-1.63%) As of 07:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
